The University of Chicago Medicine Comprehensive Cancer Center, Chicago
UChicago Medicine Comprehensive Cancer Center at Silver Cross Hospital, New Lenox
UChicago Medicine Orland Park, Orland Park

Menerima pesertaFase 1/2

Usia 18 ke atas · Semua jenis kelamin · Diperbarui 30 Sep 2026 · NCT05868226

A Study to Evaluate the Adverse Events, and Efficacy of Intravenous (IV) of Telisotuzumab Adizutecan in Combination With IV Oxaliplatin, Fluorouracil, Folinic Acid/Leucovorin, Bevacizumab, Panitumumab in Adult Participants With Metastatic Colorectal Cancer

University of Chicago Medical Center /ID# 271688, Chicago
Hope And Healing Cancer Services /ID# 271562, Hinsdale

Menerima pesertaFase 2

Usia 18 ke atas · Semua jenis kelamin · Diperbarui 28 Sep 2026 · NCT06820463

Symbiotic-GI-03: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Metastatic Colorectal Cancer

Illinois Cancer Specialists, Arlington Heights
Illinois CancerCare - Bloomington, Bloomington
Illinois Cancer Specialists, Chicago
dan 10 lainnya

Menerima pesertaFase 3

Usia 18 ke atas · Semua jenis kelamin · Diperbarui 28 Sep 2026 · NCT07222800

Phase 1 Study to Investigate TCRTs KRAS Mutation in Unresectable, Advanced, and/or Metastatic Solid Tumors

Research Site, Chicago

Menerima pesertaFase 1

Usia 18 ke atas · Semua jenis kelamin · Diperbarui 25 Sep 2026 · NCT06218914

A Study to Evaluate the Safety, Pharmacokinetics, and Anti-Tumor Activity of VVD-133214 as Monotherapy and in Combination in Participants With Advanced Solid Tumors

University of Chicago, Chicago

Menerima pesertaFase 1

Usia 18 ke atas · Semua jenis kelamin · Diperbarui 25 Sep 2026 · NCT06004245

A Study of Amivantamab and FOLFIRI Versus Cetuximab/Bevacizumab and FOLFIRI in Participants With KRAS/NRAS and BRAF Wild-type Colorectal Cancer Who Have Previously Received Chemotherapy

Illinois Cancer Specialists, Arlington Heights
Illinois CancerCare, Peoria

Menerima pesertaFase 3

Usia 18 ke atas · Semua jenis kelamin · Diperbarui 25 Sep 2026 · NCT06750094

Pressurized Intraperitoneal Aerosolized Chemotherapy With Mitomycin for the Treatment of Unresectable Appendix or Colorectal Cancer With Peritoneal Metastases, The IMPACT Trial

City of Hope at Chicago, Zion

Menerima pesertaFase 3

Usia 18 ke atas · Semua jenis kelamin · Diperbarui 25 Sep 2026 · NCT07271355

A Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer

Illinois Cancer Specialists, Arlington Heights
Illinois CancerCare, Peoria

Menerima pesertaFase 3

Usia 18 ke atas · Semua jenis kelamin · Diperbarui 25 Sep 2026 · NCT06662786

Testing Pump Chemotherapy in Addition to Standard of Care Chemotherapy Versus Standard of Care Chemotherapy Alone for Patients With Unresectable Colorectal Liver Metastases: The PUMP Trial

Northwestern University, Chicago
University of Chicago Comprehensive Cancer Center, Chicago
Northwestern Medicine Cancer Center Old Irving Park, Chicago

Menerima pesertaFase 3

Usia 18 ke atas · Semua jenis kelamin · Diperbarui 24 Sep 2026 · NCT05863195

A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Bevacizumab in Combination With Chemotherapy in Participants With Previously Untreated, Unresectable, or Metastatic Colorectal Cancer

Local Institution - 0433, Chicago

Menerima pesertaFase 2/3

Usia 18 ke atas · Semua jenis kelamin · Diperbarui 23 Sep 2026 · NCT07221357

Manipulation of the Gut Microbiome by a Standardized Preoperative Diet to Prevent Colorectal Cancer Recurrence and Metastasis Following Surgery

University of Chicago, Chicago

Menerima pesertaFase 1/2

Usia 18 ke atas · Semua jenis kelamin · Diperbarui 21 Sep 2026 · NCT06349590

A Study to Evaluate the Efficacy and Safety of Standard-of-Care Chemotherapy and Bevacizumab With or Without INCA33890 in the First-Line Treatment of Metastatic Microsatellite Stable Colorectal Cancer

Sih Cancer Institute, Carterville
University of Illinois Cancer Center, Chicago
Alexian Brothers Medical Center, Elk Grove Village
dan 2 lainnya

Menerima pesertaFase 3

Usia 18 ke atas · Semua jenis kelamin · Diperbarui 15 Sep 2026 · NCT07284849

A Study Evaluating the Safety and Efficacy of Targeted Therapies in Subpopulations of Patients With Metastatic Colorectal Cancer (INTRINSIC)

Illinois Cancer Specialists, Arlington Heights

Menerima pesertaFase 1

Usia 18 ke atas · Semua jenis kelamin · Diperbarui 11 Sep 2026 · NCT04929223

SIBYL: obServation of Therapy Response With lIquid BiopsY evaLuation

Orchard Healthcare Research Inc., Skokie

Menerima pesertaStudi observasional

Usia 18 ke atas · Semua jenis kelamin · Diperbarui 11 Sep 2026 · NCT05935384

A Study of Precemtabart Tocentecan With or Without Bevacizumab Compared to Trifluridine/Tipiracil Plus Bevacizumab in Participants With Previously Treated Metastatic Colorectal Cancer (PROCEADE-CRC-03)

Illinois Cancer Specialists, Arlington Heights
Illinois CancerCare PC, Peoria
Springfield Clinic, Springfield

Menerima pesertaFase 3

Usia 18 ke atas · Semua jenis kelamin · Diperbarui 9 Sep 2026 · NCT07549412

Clinical Trial of an Anti-cancer Drug, CA-4948 (Emavusertib), in Combination With Chemotherapy Treatment (FOLFOX Plus Bevacizumab) in Metastatic Colorectal Cancer

Memorial Hospital East, Shiloh

Menerima pesertaFase 1

Usia 18 ke atas · Semua jenis kelamin · Diperbarui 9 Sep 2026 · NCT06696768

Phase III Study of Ivonescimab or Bevacizumab Combined With FOLFOX in Patients With Metastatic Colorectal Cancer

Clinical Study Site, Chicago
Clinical Study Site, Elmhurst
Clinical Study Site, O'Fallon

Menerima pesertaFase 3

Usia 18 ke atas · Semua jenis kelamin · Diperbarui 8 Sep 2026 · NCT07228832

Study of Sotorasib, Panitumumab and FOLFIRI Versus FOLFIRI With or Without Bevacizumab-awwb in Treatment-naïve Participants With Metastatic Colorectal Cancer With KRAS p.G12C Mutation

Insight Research Institute, Chicago

Menerima pesertaFase 3

Usia 18 ke atas · Semua jenis kelamin · Diperbarui 3 Sep 2026 · NCT06252649

Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors

Lurie Children's Hospital-Chicago, Chicago

Menerima pesertaFase 1/2

12 Months – 30 Years · Semua jenis kelamin · Diperbarui 25 Agu 2026 · NCT04851119

A Study of Novel Study Interventions and Combinations in Participants With Colorectal Cancer

Research Site, Chicago

Menerima pesertaFase 2

Usia 18 hingga 130 · Semua jenis kelamin · Diperbarui 18 Agu 2026 · NCT06792695

Minimal Residual Disease Testing for the Early Detection of Cancer Recurrence in Resectable Stage II-IV Colorectal Cancer Patients

City of Hope at Chicago, Zion

Menerima peserta

Usia 18 ke atas · Semua jenis kelamin · Diperbarui 12 Agu 2026 · NCT07125729

A Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02)

Orchard Healthcare Research Inc, Skokie

Menerima pesertaFase 1/2

Usia 18 ke atas · Semua jenis kelamin · Diperbarui 5 Agu 2026 · NCT06330064

A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors

Hope and Healing Cancer Services, Hinsdale

Menerima pesertaFase 1/2

Usia 18 ke atas · Semua jenis kelamin · Diperbarui 30 Jul 2026 · NCT04657068

Safely Optimizing Body Weight With Mifomelatide (TCMCB07) in Patients With Newly Diagnosed Colorectal Cancer (CRC) or Pancreatic Ductal Adenocarcinoma (PDAC) Undergoing Chemotherapy

Northwestern University - Robert H. Lurie Comprehensive Cancer Center, Chicago
Hope and Healing Cancer Services, Hinsdale
Orchard Healthcare Research, Skokie

Menerima pesertaFase 2

Usia 18 ke atas · Semua jenis kelamin · Diperbarui 15 Jul 2026 · NCT06937177

A Study to Assess Adverse Events and Change in Disease Activity in Adult Participants Receiving Intravenously Infused Telisotuzumab Adizutecan Alone or With Standard of Care in Participants With Post Adjuvant Circulating Tumor DNA Positive Colorectal Cancer and No Radiographic Evidence of Disease

University of Chicago Medical Center /ID# 274742, Chicago

Menerima pesertaFase 2

Usia 18 ke atas · Semua jenis kelamin · Diperbarui 10 Jul 2026 · NCT07023289

Colorectal Metastasis to Liver Extraction With Auxiliary Transplant and Delayed Resection

Northwestern University-Comprehensive Transplant Center, Chicago

Menerima pesertaStudi observasional

Usia 18 ke atas · Semua jenis kelamin · Diperbarui 10 Jul 2026 · NCT06698146

CARE Tool Study Aim 3

Alton Memorial Hospital, Alton

Menerima peserta

Usia 18 ke atas · Semua jenis kelamin · Diperbarui 8 Jul 2026 · NCT07296887

A Trial to Evaluate the Safety and Activity of Fruquintinib in Minority Populations With Advanced, Previously Treated Colorectal Cancer

Hope and Healing Cancer Services, Hinsdale

Menerima pesertaFase 4

Usia 18 ke atas · Semua jenis kelamin · Diperbarui 7 Jul 2026 · NCT06562543

A Study to Investigate ALE.P03 as Monotherapy in Adult Patients With Selected Advanced or Metastatic CLDN1+ Solid Tumors

The University of Chicago Medical Center - Oncology, Chicago

Menerima pesertaFase 1/2

Usia 18 ke atas · Semua jenis kelamin · Diperbarui 2 Jul 2026 · NCT07169734

CT-95 in Advanced Cancers Associated With Mesothelin Expression

Context Investigational Site, Chicago

Menerima pesertaFase 1

Usia 18 ke atas · Semua jenis kelamin · Diperbarui 12 Jun 2026 · NCT06756035

A Study of Fruquintinib Plus FOLFIRI as Second-Line Treatment for Participants With Metastatic Colorectal Cancer (FRUITFUL)

Illinois Cancer Specialists, Arlington Heights

Menerima pesertaFase 2

Usia 18 ke atas · Semua jenis kelamin · Diperbarui 12 Jun 2026 · NCT07011576

BBO-11818 in Adult Subjects With KRAS Mutant Cancer

OSF Healthcare Cancer Institute, Peoria

Menerima pesertaFase 1

Usia 18 ke atas · Semua jenis kelamin · Diperbarui 2 Jun 2026 · NCT06917079

Exogenous and Endogenous Risk Factors for Early-onset Colorectal Cancer

Section of Gastroenterology, Hepatology, and Nutrition, Department of Medicine University of Chicago Medicine, Chicago

Menerima pesertaStudi observasionalSukarelawan sehat diterima

Usia 18 hingga 49 · Semua jenis kelamin · Diperbarui 24 Apr 2026 · NCT05732623

Dari ClinicalTrials.gov, data diambil 5 Okt 2026. Setiap studi menetapkan kriteria kelayakannya sendiri; tim studi yang menentukan siapa yang bisa bergabung.